<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19943908</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2958</ISSN><JournalIssue CitedMedium="Internet"><Volume>75</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Molecular microbiology</Title><ISOAbbreviation>Mol Microbiol</ISOAbbreviation></Journal><ArticleTitle>Comparison of Staphopain A (ScpA) and B (SspB) precursor activation mechanisms reveals unique secretion kinetics of proSspB (Staphopain B), and a different interaction with its cognate Staphostatin, SspC.</ArticleTitle><Pagination><MedlinePgn>161-77</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1365-2958.2009.06974.x</ELocationID><Abstract><AbstractText>The scpAB and sspABC operons of Staphylococcus aureus encode Staphopain cysteine proteases ScpA and SspB, and their respective Staphostatins ScpB and SspC, which are thought to protect against premature activation of Staphopain precursors during protein export. However, we found that the proSspB precursor was secreted and activated without detriment to S. aureus in the absence of SspC function. Our data indicate that this is feasible due to a restricted substrate specificity of mature SspB, a stable precursor structure and slow secretion kinetics. In contrast, mature ScpA had a broad substrate specificity, such that it was prone to autolytic degradation, but also was uniquely able to degrade elastin fibres. Modelling of proScpA relative to the proSspB structure identified several differences, which appear to optimize proScpA for autocatalytic activation, whereas proSspB is optimized for stability, and cannot initiate autocatalytic activation. Consequently, recombinant proSspB remained stable and unprocessed when retained in the cytoplasm of Escherichia coli, whereas proScpA initiated rapid autocatalytic activation, leading to capture of an activation intermediate by ScpB. We conclude that the status of sspBC in S. aureus, as paralogues of the ancestral scpAB genes, facilitated a different activation mechanism, a stable proSspB isoform and modified Staphostatin function.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nickerson</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, M4N 3M5.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ip</LastName><ForeName>Jessica</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Passos</LastName><ForeName>Daniel T</ForeName><Initials>DT</Initials></Author><Author ValidYN="Y"><LastName>McGavin</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-12669</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Microbiol</MedlineTA><NlmUniqueID>8712028</NlmUniqueID><ISSNLinking>0950-382X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011498">Protein Precursors</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-58-3</RegistryNumber><NameOfSubstance UI="D004549">Elastin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C501295">staphopain A protein, Staphylococcus aureus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C479137">staphopain B protein, Staphylococcus aureus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003593" MajorTopicYN="N">Cytoplasm</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004549" MajorTopicYN="N">Elastin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011498" MajorTopicYN="N">Protein Precursors</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055550" MajorTopicYN="N">Protein Stability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017434" MajorTopicYN="N">Protein Structure, Tertiary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013211" MajorTopicYN="N">Staphylococcus aureus</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19943908</ArticleId><ArticleId IdType="pii">MMI6974</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2958.2009.06974.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10972831</PMID><DateCompleted><Year>2000</Year><Month>11</Month><Day>15</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-382X</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><Issue>5</Issue><PubDate><Year>2000</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Molecular microbiology</Title><ISOAbbreviation>Mol Microbiol</ISOAbbreviation></Journal><ArticleTitle>The Salmonella type III secretion translocon protein SspC is inserted into the epithelial cell plasma membrane upon infection.</ArticleTitle><Pagination><MedlinePgn>1133-45</MedlinePgn></Pagination><Abstract><AbstractText>Salmonella species translocate effector proteins into the host cell cytoplasm using a type III secretion system (TTSS). The translocation machinery probably contacts the eukaryotic cell plasma membrane to effect protein transfer. Data presented here demonstrate that both SspB and SspC, components of the translocation apparatus, are inserted into the epithelial cell plasma membrane 15 min after Salmonella typhimurium infection. In addition, a yeast two-hybrid interaction between SspC and an eukaryotic intermediate filament protein was identified. Three individual carboxyl-terminal point mutations within SspC that disrupt the yeast two-hybrid interaction were isolated. Strains expressing the mutant SspC alleles were defective for invasion, translocation of effector molecules and membrane localization of SspC. These data indicate that insertion of SspC into the plasma membrane of target cells is required for invasion and effector molecule translocation and that the carboxyl terminus of SspC is essential for these functions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scherer</LastName><ForeName>C A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Departments of Microbiology and Medicine, University of Washington, Box 357710, Seattle, WA 98195-7710, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Miller</LastName><ForeName>S I</ForeName><Initials>SI</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>F32AI09312</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01AI30479</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Microbiol</MedlineTA><NlmUniqueID>8712028</NlmUniqueID><ISSNLinking>0950-382X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008565">Membrane Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094578">Salmonella invasion protein C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C094579">invasion protein B, Salmonella typhimurium</NameOfSubstance></Chemical><Chemical><RegistryNumber>68238-35-7</RegistryNumber><NameOfSubstance UI="D007633">Keratins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001692" MajorTopicYN="N">Biological Transport</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002462" MajorTopicYN="N">Cell Membrane</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004847" MajorTopicYN="N">Epithelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015870" MajorTopicYN="N">Gene Expression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007633" MajorTopicYN="N">Keratins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008565" MajorTopicYN="N">Membrane Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017354" MajorTopicYN="N">Point Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012486" MajorTopicYN="N">Salmonella typhimurium</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020798" MajorTopicYN="N">Two-Hybrid System Techniques</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>9</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>9</Month><Day>6</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10972831</ArticleId><ArticleId IdType="pii">mmi2066</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2958.2000.02066.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33741528</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>24</Day></DateCompleted><DateRevised><Year>2021</Year><Month>12</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1096-0279</ISSN><JournalIssue CitedMedium="Internet"><Volume>183</Volume><PubDate><Year>2021</Year><Month>07</Month></PubDate></JournalIssue><Title>Protein expression and purification</Title><ISOAbbreviation>Protein Expr Purif</ISOAbbreviation></Journal><ArticleTitle>Proteomic analysis reveals a role of ADP-glucose pyrophosphorylase in the asynchronous filling of rice superior and inferior spikelets.</ArticleTitle><Pagination><MedlinePgn>105875</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S1046-5928(21)00058-9</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pep.2021.105875</ELocationID><Abstract><AbstractText>The poor grain filling of inferior spikelets (IS) situated on the lower secondary rachis branch leads to a remarkable decrease in rice yield and quality. The AGPase small subunit 2 (AGPS2) encodes a small subunit of adenosine diphosphate-glucose pyrophosphorylase (AGPase) enzyme, which plays an important role in sucrose-starch conversion and starch biosynthesis in the grain filling of rice. In the present study, qPCR analysis showed low expression abundance of AGPS2 in IS, compared to the superior spikelets (SS), which was consistent with the lower grain weight of IS. To evaluate the molecular mechanism of AGPS2, we first identified the AGPS2 interaction network through Co-immunoprecipitation (Co-IP). In total, 29 proteins of AGPS2 interaction network were characterized by LC-MS/MS. Bioinformatics analysis revealed that, the characterized proteins in the interaction network are likely to be related to starch synthesis, sugar conversion, energy pathway, and folding/modification, and most of them were involved in the grain filling of rice. The sequent Co-IP analysis showed that AGPS2 can bind to starch branching enzyme (SBE), pullulanase (PUL) and starch debranching enzyme (DBE) and assemble into starch synthesizing protein complex (SSPC). In addition, the 14-3-3 protein GF14e was also found to interact with AGPS2. Further analysis by qPCR showed that the expression of GF14e was much higher on IS than on SS. The qPCR results also showed that the expression of GF14e was relatively stable in SS, but changed significantly in IS under alternate wetting and moderate soil drying (WMD), which is consistent with the AGPS2 expression pattern. Our present work provides direct molecular evidence for the different expression patterns of AGPS2 in SS and IS, which could be greatly helpful for the molecular amelioration of the poor grain filling of IS in rice.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zhou</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Key Laboratory for Genetics, Breeding and Multiple Utilization of Crops, Ministry of Education, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China; Subtropical Agriculture Research Institute, Fujian Academy of Agricultural Sciences, Zhangzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amjad</LastName><ForeName>Hira</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhong</LastName><ForeName>Guopei</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Muhammad Umar</ForeName><Initials>MU</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Zhixing</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China; Key Laboratory for Genetics, Breeding and Multiple Utilization of Crops, Ministry of Education, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China. Electronic address: zhangzhixingfz@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Wenxiong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>College of Life Sciences, Fujian Agricultural and Forestry University, Fuzhou, Fujian, China; Fujian Provincial Key Laboratory of Agroecological Processing and Safety Monitoring, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China; Key Laboratory for Genetics, Breeding and Multiple Utilization of Crops, Ministry of Education, Fujian Agriculture and Forestry University, Fuzhou, Fujian, China. Electronic address: lwx@fafu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Protein Expr Purif</MedlineTA><NlmUniqueID>9101496</NlmUniqueID><ISSNLinking>1046-5928</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010940">Plant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9005-25-8</RegistryNumber><NameOfSubstance UI="D013213">Starch</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.7.27</RegistryNumber><NameOfSubstance UI="D051599">Glucose-1-Phosphate Adenylyltransferase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051599" MajorTopicYN="N">Glucose-1-Phosphate Adenylyltransferase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012275" MajorTopicYN="N">Oryza</DescriptorName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010940" MajorTopicYN="N">Plant Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D040901" MajorTopicYN="Y">Proteomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013213" MajorTopicYN="N">Starch</DescriptorName><QualifierName UI="Q000096" MajorTopicYN="Y">biosynthesis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">AGPS2</Keyword><Keyword MajorTopicYN="Y">Grain-filling</Keyword><Keyword MajorTopicYN="Y">Inferior spikelets</Keyword><Keyword MajorTopicYN="Y">Rice</Keyword><Keyword MajorTopicYN="Y">Superior spikelets</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>09</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>02</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>3</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>3</Month><Day>20</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33741528</ArticleId><ArticleId IdType="pii">S1046-5928(21)00058-9</ArticleId><ArticleId IdType="doi">10.1016/j.pep.2021.105875</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30259745</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-8392</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>11</Issue><PubDate><Year>2018</Year><Month>11</Month><Day>05</Day></PubDate></JournalIssue><Title>Molecular pharmaceutics</Title><ISOAbbreviation>Mol Pharm</ISOAbbreviation></Journal><ArticleTitle>Investigation of the Dependence of the Flory-Huggins Interaction Parameter on Temperature and Composition in a Drug-Polymer System.</ArticleTitle><Pagination><MedlinePgn>5327-5335</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.8b00797</ELocationID><Abstract><AbstractText>The Flory-Huggins (F-H) solubility equation has been widely used to describe the solubility of a small-molecule drug in a polymeric carrier and thus determine the design space available for formulating a stable amorphous solid dispersion. The F-H interaction parameter (χ) describes the thermodynamic properties of drug-polymer solutions and accounts for any enthalpic and entropic changes in solubility. Many studies have found that for a limited compositional range, χ varies proportionally to the inverse of the melting temperature of the drug. We explored this relationship using a highly sensitive DSC technique to detect remaining residual crystalline active pharmaceutical ingredients (APIs) following annealing of ball milled mixtures of crystalline itraconazole (ITZ) and either Soluplus or hydroxypropyl methylcellulose phthalate (HPMCP) at temperatures near the estimated solubility curve. Depending on the experimental approach taken, the measurement of drug-polymer solubility can be restricted to mixtures with a high proportion of drug, but in this study, solubility was experimentally determined for mixtures with API content as low as 10 wt %. Results suggest that the proposed linear relationship does not extend to compositions with smaller amounts of API, instead indicating that χ was both temperature- and composition-dependent for the systems studied. The feasibility of this technique to measure interactions in a ternary system containing itraconazole and both polymers was also determined; ITZ-HPMCP exhibited the most favorable values of χ, while ITZ-Soluplus and ITZ-Soluplus-HPMCP demonstrated similar interaction parameters.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Potter</LastName><ForeName>Catherine B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0001-5332-4576</Identifier><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute , University of Limerick , Limerick V94 T9PX , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><Identifier Source="ORCID">0000-0002-1775-885X</Identifier><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute , University of Limerick , Limerick V94 T9PX , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albadarin</LastName><ForeName>Ahmad B</ForeName><Initials>AB</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute , University of Limerick , Limerick V94 T9PX , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Gavin M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute , University of Limerick , Limerick V94 T9PX , Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharm</MedlineTA><NlmUniqueID>101197791</NlmUniqueID><ISSNLinking>1543-8384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002152" MajorTopicYN="N">Calorimetry, Differential Scanning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004339" MajorTopicYN="N">Drug Compounding</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="Y">Temperature</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Flory−Huggins</Keyword><Keyword MajorTopicYN="Y">amorphous solid dispersion</Keyword><Keyword MajorTopicYN="Y">drug−polymer solubility</Keyword><Keyword MajorTopicYN="Y">high-speed differential scanning calorimetry</Keyword><Keyword MajorTopicYN="Y">phase diagram</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30259745</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00797</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">31971802</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6904</ISSN><JournalIssue CitedMedium="Internet"><Volume>85</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>02</Month><Day>21</Day></PubDate></JournalIssue><Title>The Journal of organic chemistry</Title><ISOAbbreviation>J Org Chem</ISOAbbreviation></Journal><ArticleTitle>One-Pot Cross-Coupling/C-H Functionalization Reactions: Quinoline as a Substrate and Ligand through N-Pd Interaction.</ArticleTitle><Pagination><MedlinePgn>2585-2596</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.joc.9b03321</ELocationID><Abstract><AbstractText>Herein, we report a one-pot process that marries mechanistically distinct, traditional cross-coupling reactions with C-H functionalization using the same precatalyst. The reactions proceed in yields of up to 95%, in air, and require no extraneous ligand. The reactions are thought to be facilitated by harnessing the substrate quinoline as an <i>N</i>-ligand, and evidence of the palladium-quinoline interaction is provided by <sup>1</sup>H-<sup>15</sup>N HMBC NMR spectroscopy and X-ray crystallographic structures. Application of the methodology is demonstrated by the quick formation of fluorescent, π-extended frameworks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shanahan</LastName><ForeName>Rachel M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>School of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hickey</LastName><ForeName>Aobha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bateman</LastName><ForeName>Lorraine M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>School of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Pharmacy , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Light</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Chemistry , University of Southampton , Southampton SO17 1BJ , United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGlacken</LastName><ForeName>Gerard P</ForeName><Initials>GP</Initials><Identifier Source="ORCID">0000-0002-7821-0804</Identifier><AffiliationInfo><Affiliation>School of Chemistry, Analytical and Biological Chemistry Research Facility (ABCRF) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC) , University College Cork , Cork T12 YN60 , Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>01</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Org Chem</MedlineTA><NlmUniqueID>2985193R</NlmUniqueID><ISSNLinking>0022-3263</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31971802</ArticleId><ArticleId IdType="doi">10.1021/acs.joc.9b03321</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">11044450</PMID><DateCompleted><Year>2001</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>276</Volume><Issue>3</Issue><PubDate><Year>2001</Year><Month>Jan</Month><Day>19</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>N-terminal amino acid residues mediate protein-protein interactions between DNA-bound alpha /beta -type small, acid-soluble spore proteins from Bacillus species.</ArticleTitle><Pagination><MedlinePgn>2267-75</MedlinePgn></Pagination><Abstract><AbstractText>The binding of alpha/beta-type small, acid-soluble spore proteins (SASP) to DNA of spores of Bacillus species is the major determinant of DNA resistance to a variety of damaging treatments. The primary sequence of alpha/beta-type SASP is highly conserved; however, the N-terminal third of these proteins is less well conserved than the C-terminal two-thirds. To determine the functional importance of residues in the N-terminal region of alpha/beta-type SASP, variants of SspC (a minor alpha/beta-type SASP from Bacillus subtilis) with modified N termini were generated and their structural and DNA binding properties studied in vitro and in vivo. SspC variants with deletions of up to 14 residues ( approximately 20% of SspC residues) were able to bind DNA in vitro and adopted similar conformations when bound to DNA, as determined by circular dichroism spectroscopy and protein-protein cross-linking. Progressive deletion of up to 11 N-terminal residues resulted in proteins with progressively lower DNA binding affinity. However, SspC(Delta)(14) (in which 14 N-terminal residues have been deleted) showed significantly higher affinity for DNA than the larger proteins, SspC(Delta)(10) and SspC(Delta)(11). The affinity of these proteins for DNA was shown to be largely dependent upon the charge of the first few N-terminal residues. These results are interpreted in the context of a model for DNA-dependent alpha/beta-type SASP protein-protein interaction involving the N-terminal regions of these proteins.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>C S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarcon-Hernandez</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Setlow</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM19698</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2000</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000143">Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017931">DNA Primers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.21.4</RegistryNumber><NameOfSubstance UI="D014357">Trypsin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000143" MajorTopicYN="N">Acids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001412" MajorTopicYN="N">Bacillus subtilis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001483" MajorTopicYN="N">Base Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017931" MajorTopicYN="N">DNA Primers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010449" MajorTopicYN="N">Peptide Mapping</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013171" MajorTopicYN="N">Spores, Bacterial</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014357" MajorTopicYN="N">Trypsin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>4</Month><Day>17</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">11044450</ArticleId><ArticleId IdType="doi">10.1074/jbc.M007858200</ArticleId><ArticleId IdType="pii">S0021-9258(18)46738-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">29183857</PMID><DateCompleted><Year>2018</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2018</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>536</Volume><Issue>1</Issue><PubDate><Year>2018</Year><Month>Jan</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Understanding the generation and maintenance of supersaturation during the dissolution of amorphous solid dispersions using modulated DSC and <sup>1</sup>H NMR.</ArticleTitle><Pagination><MedlinePgn>414-425</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(17)31111-0</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2017.11.056</ELocationID><Abstract><AbstractText>In this study, the dissolution behaviour of dipyridamole (DPM) and cinnarizine (CNZ) spray-dried amorphous solid dispersions (ASDs) using polyvinyl pyrrolidone (PVP) and polyacrylic acid (PAA) as a carrier matrix were evaluated and compared. The drug concentrations achieved from the dissolution of PVP and PAA solid dispersions were significantly greater than the equilibrium solubility of crystalline DPM and CNZ in phosphate buffer pH 6.8 (PBS 6.8). The maximum drug concentration achieved by dissolution of PVP and PAA solid dispersions did not exceed the theoretically calculated apparent solubility of amorphous DPM and CNZ. However, the degree of supersaturation of DPM and CNZ increased considerably as the polymer weight fraction within the solid dispersion increased. In addition, the supersaturation profile of DPM and CNZ were studied in the presence and absence of the polymers. PAA was found to maintain a higher level of supersaturation compared to PVP. The enhanced drug solution concentration following dissolution of ASDs can be attributed to the reduced crystal growth rates of DPM and CNZ at an equivalent supersaturation. We have also shown that, for drugs having high crystallization tendency and weak drug-polymer interaction, the feasible way to increase dissolution might be increase the polymer weight fraction in the ASD. Solution <sup>1</sup>H NMR spectra were used to understand dissolution mechanism and to identify drug-polymer interaction. The change in electron densities of proton attached to different groups in DPM and CNZ suggested drug-polymer interaction in solution. The relative intensities of peak shift and nature of interaction between drug and polymer in different systems are different. These different effects suggest that DPM and CNZ interacts in a different way with PVP and PAA in solution which goes some way towards explaining the different polymeric effect, particularly in terms of inhibition of drug recrystallization and dissolution of DPM and CNZ ASDs. These results established that the different drug/polymer interactions in the solid state and in solution give rise to the variation in dissolution profile observed for different systems.</AbstractText><CopyrightInformation>Copyright © 2017 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baghel</LastName><ForeName>Shrawan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Cork Road, Waterford, Ireland. Electronic address: baghel.shrawan@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cathcart</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Cork Road, Waterford, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Niall J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Cork Road, Waterford, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000180">Acrylic Resins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004337">Drug Carriers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>3DI2E1X18L</RegistryNumber><NameOfSubstance UI="D002936">Cinnarizine</NameOfSubstance></Chemical><Chemical><RegistryNumber>4Q93RCW27E</RegistryNumber><NameOfSubstance UI="C006903">carbopol 940</NameOfSubstance></Chemical><Chemical><RegistryNumber>64ALC7F90C</RegistryNumber><NameOfSubstance UI="D004176">Dipyridamole</NameOfSubstance></Chemical><Chemical><RegistryNumber>FZ989GH94E</RegistryNumber><NameOfSubstance UI="D011205">Povidone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000180" MajorTopicYN="N">Acrylic Resins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002936" MajorTopicYN="N">Cinnarizine</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004176" MajorTopicYN="N">Dipyridamole</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004337" MajorTopicYN="N">Drug Carriers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011205" MajorTopicYN="N">Povidone</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D066244" MajorTopicYN="N">Proton Magnetic Resonance Spectroscopy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amorphous solid dispersion</Keyword><Keyword MajorTopicYN="N">Crystallization</Keyword><Keyword MajorTopicYN="N">Dissolution</Keyword><Keyword MajorTopicYN="N">Drug-polymer interaction</Keyword><Keyword MajorTopicYN="N">Nuclear magnetic resonance</Keyword><Keyword MajorTopicYN="N">Spray drying</Keyword><Keyword MajorTopicYN="N">Supersaturation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>10</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2017</Year><Month>11</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>11</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29183857</ArticleId><ArticleId IdType="pii">S0378-5173(17)31111-0</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2017.11.056</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">12890028</PMID><DateCompleted><Year>2004</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0950-382X</ISSN><JournalIssue CitedMedium="Print"><Volume>49</Volume><Issue>4</Issue><PubDate><Year>2003</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Molecular microbiology</Title><ISOAbbreviation>Mol Microbiol</ISOAbbreviation></Journal><ArticleTitle>Staphostatins: an expanding new group of proteinase inhibitors with a unique specificity for the regulation of staphopains, Staphylococcus spp. cysteine proteinases.</ArticleTitle><Pagination><MedlinePgn>1051-66</MedlinePgn></Pagination><Abstract><AbstractText>A novel type of cysteine proteinase inhibitor (SspC) has been recently recognized in Staphylococcus aureus (Massimi, I., Park, E., Rice, K., Muller-Esterl, W., Sauder, D.N., and McGavin, M.J. (2002) J Biol Chem 277: 41770-41777). In this paper we have identified homologous proteins encoded in the genome of S. aureus and other coagulase-negative Staphylococci. Collectively we refer to these proteins as staphostatins as they specifically inhibit cysteine proteinases (staphopains) from Staphylococcus spp. The primary structure of staphostatins seems to be unique, although they resemble cystatins in size (105-108 residues). Recombinant staphostatin A, a product of the scpB gene and staphostatin B (SspC) from S. aureus have been characterized in details. Similar to the cystatins, the staphostatins interact specifically with their target proteinases forming tight and stable non-covalent complexes, staphostatin A with staphopain A and staphostatin B with staphopain B. However, in contrast to the cystatins, each of which inhibits broad range of cathepsins, complex formation between staphostatin and staphopain appears to be exclusive, with no cross interaction observed. In addition, the activities of several tested cysteine proteinases of prokaryotic- and eukaryotic-origin were not affected by staphostatins. Such narrow specificity limited to staphopains is presumed to be required to protect staphylococcal cytoplasmic proteins from being degraded by prematurely activated/folded prostaphopains. This function is guaranteed through the unique co-expression of the secreted proteinase and the intracellular inhibitor from the same operon, and represents a unique mechanism of regulation of proteolytic activity in Gram-positive bacteria.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rzychon</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Analytical Biochemistry, Faculty of Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Kraków, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sabat</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kosowska</LastName><ForeName>Klaudia</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Potempa</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dubin</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Microbiol</MedlineTA><NlmUniqueID>8712028</NlmUniqueID><ISSNLinking>0950-382X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D047908">Intracellular Signaling Peptides and Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D046911">Macromolecular Substances</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C479136">staphostatin B protein, Staphylococcus aureus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C479137">staphopain B protein, Staphylococcus aureus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002458" MajorTopicYN="N">Cell Fractionation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047908" MajorTopicYN="N">Intracellular Signaling Peptides and Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D046911" MajorTopicYN="N">Macromolecular Substances</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008745" MajorTopicYN="N">Methylation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009876" MajorTopicYN="N">Operon</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019032" MajorTopicYN="N">Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013210" MajorTopicYN="N">Staphylococcus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>3</Month><Day>9</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2003</Year><Month>8</Month><Day>2</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">12890028</ArticleId><ArticleId IdType="pii">3613</ArticleId><ArticleId IdType="doi">10.1046/j.1365-2958.2003.03613.x</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">10954716</PMID><DateCompleted><Year>2001</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>02</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0021-9258</ISSN><JournalIssue CitedMedium="Print"><Volume>275</Volume><Issue>45</Issue><PubDate><Year>2000</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>The Journal of biological chemistry</Title><ISOAbbreviation>J Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Equilibrium and kinetic binding interactions between DNA and a group of novel, nonspecific DNA-binding proteins from spores of Bacillus and Clostridium species.</ArticleTitle><Pagination><MedlinePgn>35040-50</MedlinePgn></Pagination><Abstract><AbstractText>Binding of alpha/beta-type small acid-soluble spore proteins (SASP) is the major determinant of DNA resistance to damage caused by UV radiation, heat, and oxidizing agents in spores of Bacillus and Clostridium species. Analysis of several alpha/beta-type SASP showed that these proteins have essentially no secondary structure in the absence of DNA, but become significantly alpha-helical upon binding to double-stranded DNAs or oligonucleotides. Folding of alpha/beta-type SASP induced by a variety of DNAs and oligonucleotides was measured by CD spectroscopy, and this allowed determination of a DNA binding site size of 4 base pairs as well as equilibrium binding parameters of the alpha/beta-type SASP-DNA interaction. Analysis of the equilibrium binding data further allowed determination of both intrinsic binding constants (K) and cooperativity factors (omega), as the alpha/beta-type SASP-DNA interaction was significantly cooperative, with the degree of cooperativity depending on both the bound DNA and the salt concentration. Kinetic analysis of the interaction of one alpha/beta-type SASP, SspC(Tyr), with DNA indicated that each binding event involves the dimerization of SspC(Tyr) monomers at a DNA binding site. The implications of these findings for the structure of the alpha/beta-type SASP.DNA complex and the physiology of alpha/beta-type SASP degradation during spore germination are discussed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hayes</LastName><ForeName>C S</ForeName><Initials>CS</Initials><AffiliationInfo><Affiliation>Department of Biochemistry, University of Connecticut Health Center, Farmington, Connecticut 06030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Z Y</ForeName><Initials>ZY</Initials></Author><Author ValidYN="Y"><LastName>Setlow</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GM19698</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM54533</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013487">Research Support, U.S. Gov't, P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biol Chem</MedlineTA><NlmUniqueID>2985121R</NlmUniqueID><ISSNLinking>0021-9258</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009841">Oligonucleotides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012808">Sigma Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014157">Transcription Factors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C092468">spoIIR protein, Bacillus subtilis</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C030069">spore-specific proteins, Bacillus</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001407" MajorTopicYN="N">Bacillus</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001665" MajorTopicYN="N">Binding Sites</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002942" MajorTopicYN="N">Circular Dichroism</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003013" MajorTopicYN="N">Clostridium</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019281" MajorTopicYN="N">Dimerization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004926" MajorTopicYN="N">Escherichia coli</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009841" MajorTopicYN="N">Oligonucleotides</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011485" MajorTopicYN="N">Protein Binding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011487" MajorTopicYN="N">Protein Conformation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017433" MajorTopicYN="N">Protein Structure, Secondary</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012808" MajorTopicYN="Y">Sigma Factor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013171" MajorTopicYN="N">Spores, Bacterial</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013696" MajorTopicYN="N">Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014157" MajorTopicYN="Y">Transcription Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014466" MajorTopicYN="N">Ultraviolet Rays</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year><Month>8</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2001</Year><Month>2</Month><Day>28</Day><Hour>10</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2000</Year><Month>8</Month><Day>24</Day><Hour>11</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">10954716</ArticleId><ArticleId IdType="doi">10.1074/jbc.M005669200</ArticleId><ArticleId IdType="pii">S0021-9258(20)88798-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15255187</PMID><DateCompleted><Year>2005</Year><Month>01</Month><Day>27</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1431-6730</ISSN><JournalIssue CitedMedium="Print"><Volume>385</Volume><Issue>6</Issue><PubDate><Year>2004</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Biological chemistry</Title><ISOAbbreviation>Biol Chem</ISOAbbreviation></Journal><ArticleTitle>Characterisation of a highly specific, endogenous inhibitor of cysteine protease from Staphylococcus epidermidis, a new member of the staphostatin family.</ArticleTitle><Pagination><MedlinePgn>543-6</MedlinePgn></Pagination><Abstract><AbstractText>Staphostatins, a novel family of cysteine protease inhibitors with a unique mechanism of action and distinct protein fold has recently been discovered. In this report we describe the properties of Staphylococcus epidermidis staphostatin A (EcpB), a new member of the family. As for other staphostatins, the recombinant S. epidermidis staphostatin A exerted very narrow inhibitory specificity, limited to cysteine protease from the same species. The closely related proteases from S. aureus cleaved the inhibitor at the reactive site peptide bond and inactivated it. The EcpB homologue, S. aureus staphostatin A (ScpB), was also susceptible to proteolytic cleavage at the same site by non-target cysteine proteases. Conversely, S. aureus staphostatin B (SspC) was resistant to such proteolysis. The difference in the susceptibility of individual inhibitors to proteolytic cleavage at the reactive site suggests subtle variations in the mechanism of interaction with cysteine proteases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dubin</LastName><ForeName>Grzegorz</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Faculty of Biotechnology, Jagiellonian University, ul. Gronostajowa 7, 30-387 Krakow, Poland. gdubin@mol.uj.edu.pl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stec-Niemczyk</LastName><ForeName>Justyna</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dylag</LastName><ForeName>Tomasz</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Silberring</LastName><ForeName>Jerzy</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Dubin</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Potempa</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Biol Chem</MedlineTA><NlmUniqueID>9700112</NlmUniqueID><ISSNLinking>1431-6730</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001426">Bacterial Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D002352">Carrier Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015853">Cysteine Proteinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495491">staphostatin A, Staphylococcus epidermidis</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001426" MajorTopicYN="N">Bacterial Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002352" MajorTopicYN="N">Carrier Proteins</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015853" MajorTopicYN="N">Cysteine Proteinase Inhibitors</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013212" MajorTopicYN="N">Staphylococcus epidermidis</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000201" MajorTopicYN="Y">enzymology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013379" MajorTopicYN="N">Substrate Specificity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>1</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>7</Month><Day>17</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15255187</ArticleId><ArticleId IdType="doi">10.1515/BC.2004.064</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">34933052</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-4995</ISSN><JournalIssue CitedMedium="Internet"><Volume>341</Volume><PubDate><Year>2022</Year><Month>01</Month></PubDate></JournalIssue><Title>Journal of controlled release : official journal of the Controlled Release Society</Title><ISOAbbreviation>J Control Release</ISOAbbreviation></Journal><ArticleTitle>Self-assembling, supramolecular chemistry and pharmacology of amphotericin B: Poly-aggregates, oligomers and monomers.</ArticleTitle><Pagination><MedlinePgn>716-732</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0168-3659(21)00672-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jconrel.2021.12.019</ELocationID><Abstract><AbstractText>Antifungal drugs such as amphotericin B (AmB) interact with lipids and phospholipids located on fungal cell membranes to disrupt them and create pores, leading to cell apoptosis and therefore efficacy. At the same time, the interaction can also take place with cell components from mammalian cells, leading to toxicity. AmB was selected as a model antifungal drug due to the complexity of its supramolecular chemical structure which can self-assemble in three different aggregation states in aqueous media: monomer, oligomer (also known as dimer) and poly-aggregate. The interplay between AmB self-assembly and its efficacy or toxicity against fungal or mammalian cells is not yet fully understood. To the best of our knowledge, this is the first report that investigates the role of excipients in the supramolecular chemistry of AmB and the impact on its biological activity and toxicity. The monomeric state was obtained by complexation with cyclodextrins resulting in the most toxic state, which was attributed to the greater production of highly reactive oxygen species upon disruption of mammalian cell membranes, a less specific mechanism of action compared to the binding to the ergosterol located in fungal cell membranes. The interaction between AmB and sodium deoxycholate resulted in the oligomeric and poly-aggregated forms which bound more selectively to the ergosterol of fungal cell membranes. NMR combined with XRD studies elucidated the interaction between drug and excipient to achieve the AmB aggregation states, and ultimately, their diffusivity across membranes. A linear correlation between particle size and the efficacy/toxicity ratio was established allowing to modulate the biological effect of the drug and hence, to improve pharmacological regimens. However, particle size is not the only factor modulating the biological response but also the equilibrium of each state which dictates the fraction of free monomeric form available. Tuning the aggregation state of AmB formulations is a promising strategy to trigger a more selective response against fungal cells and to reduce the toxicity in mammalian cells.</AbstractText><CopyrightInformation>Copyright © 2021. Published by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fernández-García</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Departamento de Farmacia Galénica y Tecnología Alimentaria, Instituto Universitario de Farmacia Industrial Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muñoz-García</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fabian</LastName><ForeName>Laszlo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, Norwich, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>González-Burgos</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Departamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gómez-Serranillos</LastName><ForeName>M Pilar</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Departamento de Farmacología, Farmacognosia y Botánica, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Raposo</LastName><ForeName>Rafaela</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Sección Departamental de Fisiología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bolás-Fernández</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Departamento de Microbiología y Parasitología, Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ballesteros</LastName><ForeName>M Paloma</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Departamento de Farmacia Galénica y Tecnología Alimentaria, Instituto Universitario de Farmacia Industrial Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Healy</LastName><ForeName>Anne Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>SSPC The Science Foundation Ireland Research Centre for Pharmaceuticals, School of Pharmacy and Pharmaceutical Sciences, Trinity College Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khimyak</LastName><ForeName>Yaroslav Z</ForeName><Initials>YZ</Initials><AffiliationInfo><Affiliation>School of Pharmacy, University of East Anglia, Norwich Research Park, NR4 7TJ, Norwich, United Kingdom. Electronic address: Y.Khimyak@uea.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>Dolores R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Departamento de Farmacia Galénica y Tecnología Alimentaria, Instituto Universitario de Farmacia Industrial Facultad de Farmacia, Universidad Complutense de Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain. Electronic address: drserran@ucm.es.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/T044020/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Control Release</MedlineTA><NlmUniqueID>8607908</NlmUniqueID><ISSNLinking>0168-3659</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000935">Antifungal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010743">Phospholipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>005990WHZZ</RegistryNumber><NameOfSubstance UI="D003840">Deoxycholic Acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>7XU7A7DROE</RegistryNumber><NameOfSubstance UI="D000666">Amphotericin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>Z30RAY509F</RegistryNumber><NameOfSubstance UI="D004875">Ergosterol</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000666" MajorTopicYN="Y">Amphotericin B</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000935" MajorTopicYN="Y">Antifungal Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003840" MajorTopicYN="N">Deoxycholic Acid</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004875" MajorTopicYN="N">Ergosterol</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008322" MajorTopicYN="N">Mammals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010743" MajorTopicYN="N">Phospholipids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Aggregation states</Keyword><Keyword MajorTopicYN="Y">Amphotericin B</Keyword><Keyword MajorTopicYN="Y">Dimer</Keyword><Keyword MajorTopicYN="Y">Monomer</Keyword><Keyword MajorTopicYN="Y">NMR</Keyword><Keyword MajorTopicYN="Y">Oligomer</Keyword><Keyword MajorTopicYN="Y">Poly-aggregate</Keyword><Keyword MajorTopicYN="Y">ROS</Keyword><Keyword MajorTopicYN="Y">Self-assembly</Keyword><Keyword MajorTopicYN="Y">Supramolecular chemistry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>12</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>20</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34933052</ArticleId><ArticleId IdType="pii">S0168-3659(21)00672-6</ArticleId><ArticleId IdType="doi">10.1016/j.jconrel.2021.12.019</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">35288220</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>13</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3476</ISSN><JournalIssue CitedMedium="Internet"><Volume>618</Volume><PubDate><Year>2022</Year><Month>Apr</Month><Day>25</Day></PubDate></JournalIssue><Title>International journal of pharmaceutics</Title><ISOAbbreviation>Int J Pharm</ISOAbbreviation></Journal><ArticleTitle>Development and characterization of a spray-dried inhalable ciprofloxacin-quercetin co-amorphous system.</ArticleTitle><Pagination><MedlinePgn>121657</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0378-5173(22)00212-5</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijpharm.2022.121657</ELocationID><Abstract><AbstractText>Spray drying is an increasingly used particle engineering technique for the production of dry powders for inhalation. However, the amorphous nature of most spray-dried particles remains a big challenge affecting both the chemical and the physical stability of the dried particles. Here, we study the possibility of producing co-amorphous ciprofloxacin-quercetin inhalable particles with improved amorphous stability compared to the individual amorphous drugs. Ciprofloxacin (CIP), a broad-spectrum antibiotic, was co-spray dried with quercetin (QUE), a compound with antibiofilm properties, from an ethanol-water co-solvent system at 2:1, 1:1 and 1:2 M ratios to investigate the formation of co-amorphous CIP-QUE particles. Differential scanning colorimetry (DSC) and X-ray powder diffraction (XRPD) were used for solid-state characterization; dynamic vapor sorption (DVS) was used for investigating the moisture sorption behaviour. The intermolecular interaction was studied via solution-state nuclear magnetic resonance (NMR) and Fourier transform infrared (FTIR) spectroscopy; the miscibility of the drugs was predicted via free energy calculations based on the Flory-Huggins interaction parameter (χ). A next generation impactor (NGI) was used to study the in vitro aerosol performance of the spray-dried powders. The physicochemical characteristics such as particle size, density, morphology, cohesion, water content and saturation solubility of the spray-dried powders were also studied. The co-spray-dried CIP-QUE powders prepared at the three molar ratios were predominantly amorphous. However, differences were observed between sample types. It was found that at a molar ratio of 1:1, CIP and QUE form a single co-amorphous system. However, increasing the molar ratio of either drug results in the formation of an additional amorphous phase, formed from the excess of the corresponding drug. Despite these differences, DVS showed that elevated humidity had a much lower influence on all three co-amorphous systems compared with the individual amorphous drugs. In vitro aerosolization study showed co-deposition of the two drugs from CIP-QUE powders with a desirable aerosol performance (ED ∼ 72-94%; FPF ∼ 48-65%) whereas QUE-only amorphous powder had an ED of 36% and a FPF of 22%. In summary, spray-dried CIP-QUE combinations resulted in co-amorphous systems with boosted stability and improved aerosol performance with the 1:1 M ratio exhibiting the greatest improvement.</AbstractText><CopyrightInformation>Copyright © 2022 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alhajj</LastName><ForeName>Nasser</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Waterford, Ireland. Electronic address: nasser.al-hajj@postgrad.wit.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Niall J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Waterford, Ireland; SSPC - The Science Foundation Ireland Research Centre for Pharmaceuticals, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cathcart</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC), Waterford Institute of Technology, Waterford, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int J Pharm</MedlineTA><NlmUniqueID>7804127</NlmUniqueID><ISSNLinking>0378-5173</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000336">Aerosols</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011208">Powders</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>5E8K9I0O4U</RegistryNumber><NameOfSubstance UI="D002939">Ciprofloxacin</NameOfSubstance></Chemical><Chemical><RegistryNumber>9IKM0I5T1E</RegistryNumber><NameOfSubstance UI="D011794">Quercetin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000336" MajorTopicYN="N">Aerosols</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002939" MajorTopicYN="Y">Ciprofloxacin</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058995" MajorTopicYN="Y">Dry Powder Inhalers</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010316" MajorTopicYN="N">Particle Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011208" MajorTopicYN="N">Powders</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011794" MajorTopicYN="N">Quercetin</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Ciprofloxacin</Keyword><Keyword MajorTopicYN="N">Co-amorphous system</Keyword><Keyword MajorTopicYN="N">Cystic fibrosis</Keyword><Keyword MajorTopicYN="N">Dry powder inhaler</Keyword><Keyword MajorTopicYN="N">Pseudomonas aeruginosa</Keyword><Keyword MajorTopicYN="N">Quercetin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>03</Month><Day>05</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>03</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>15</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35288220</ArticleId><ArticleId IdType="pii">S0378-5173(22)00212-5</ArticleId><ArticleId IdType="doi">10.1016/j.ijpharm.2022.121657</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33897974</PMID><DateRevised><Year>2021</Year><Month>05</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2001-0370</ISSN><JournalIssue CitedMedium="Print"><Volume>19</Volume><PubDate><Year>2021</Year></PubDate></JournalIssue><Title>Computational and structural biotechnology journal</Title><ISOAbbreviation>Comput Struct Biotechnol J</ISOAbbreviation></Journal><ArticleTitle>Enzyme kinetic and binding studies identify determinants of specificity for the immunomodulatory enzyme ScpA, a C5a inactivating bacterial protease.</ArticleTitle><Pagination><MedlinePgn>2356-2365</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.csbj.2021.04.024</ELocationID><Abstract><AbstractText>The Streptococcal C5a peptidase (ScpA) specifically inactivates the human complement factor hC5a, a potent anaphylatoxin recently identified as a therapeutic target for treatment of COVID-19 infections. Biologics used to modulate hC5a are predominantly monoclonal antibodies. Here we present data to support an alternative therapeutic approach based on the specific inactivation of hC5a by ScpA in studies using recombinant hC5a (rhC5a). Initial characterization of ScpA confirmed activity in human serum and against rhC5a desArg (rhC5a<sub>dR</sub>), the predominant hC5a form in blood. A new FRET based enzyme assay showed that ScpA cleaved rhC5a at near physiological concentrations (<i>K</i> <sub>m</sub> 185 nM). Surface Plasmon Resonance (SPR) and Isothermal Titration Calorimetry (ITC) studies established a high affinity ScpA-rhC5a interaction (<i>K</i> <sub>D</sub> 34 nM, <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML"> <mml:mrow> <mml:msubsup><mml:mrow><mml:mi>K</mml:mi></mml:mrow> <mml:mrow><mml:mi>D</mml:mi></mml:mrow> <mml:mrow><mml:mi>ITC</mml:mi></mml:mrow> </mml:msubsup> </mml:mrow> </mml:math> 30.8 nM). SPR analyses also showed that substrate binding is dominated (88% of ΔG°<sub>bind</sub>) by interactions with the bulky N-ter cleavage product (P<sub>N</sub>, 'core' residues 1-67) with interactions involving the C-ter R74 contributing most of the remaining ΔG°<sub>bind</sub>. Furthermore, reduced binding affinity following mutation of a subset of positively charged Arginine residues of P<sub>N</sub> and in the presence of higher salt concentrations, highlighted the importance of electrostatic interactions. These data provide the first in-depth study of the ScpA-C5a interaction and indicate that ScpA's ability to efficiently cleave physiological concentrations of C5a is driven by electrostatic interactions between an exosite on the enzyme and the 'core' of C5a. The results and methods described herein will facilitate engineering of ScpA to enhance its potential as a therapeutic for excessive immune response to infectious disease.</AbstractText><CopyrightInformation>© 2021 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teçza</LastName><ForeName>Malgorzata</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Sciences, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kagawa</LastName><ForeName>Todd F</ForeName><Initials>TF</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SSPC, University of Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooney</LastName><ForeName>Jakki C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Biological Sciences, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bernal Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>SSPC, University of Limerick, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Comput Struct Biotechnol J</MedlineTA><NlmUniqueID>101585369</NlmUniqueID><ISSNLinking>2001-0370</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">C5a peptidase</Keyword><Keyword MajorTopicYN="N">COVID-19, cell envelope protease</Keyword><Keyword MajorTopicYN="N">Complement factor C5a</Keyword><Keyword MajorTopicYN="N">Immune modulation</Keyword><Keyword MajorTopicYN="N">Substrate specificity</Keyword></KeywordList><CoiStatement>The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: JCC and TFK are inventors on a patent for the development of ScpA as a therapeutic for sepsis, licenced to a company through the University of Limerick.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>04</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>26</Day><Hour>5</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33897974</ArticleId><ArticleId IdType="doi">10.1016/j.csbj.2021.04.024</ArticleId><ArticleId IdType="pii">S2001-0370(21)00136-7</ArticleId><ArticleId IdType="pmc">PMC8052502</ArticleId></ArticleIdList><?pmcsd ?><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1985 Dec;82(23):8144-8</Citation><ArticleIdList><ArticleId IdType="pubmed">3906656</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1988 Nov 15;141(10):3570-4</Citation><ArticleIdList><ArticleId IdType="pubmed">3183381</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1999 Aug 13;274(33):23229-34</Citation><ArticleIdList><ArticleId IdType="pubmed">10438496</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 2002 Jun;70(6):2869-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12010974</ArticleId></ArticleIdList></Reference><Reference><Citation>Comput Struct Biotechnol J. 2020 Mar 13;18:650-660</Citation><ArticleIdList><ArticleId IdType="pubmed">32257048</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2019 Sep;18(9):707-729</Citation><ArticleIdList><ArticleId IdType="pubmed">31324874</ArticleId></ArticleIdList></Reference><Reference><Citation>Surgery. 1981 Aug;90(2):319-27</Citation><ArticleIdList><ArticleId IdType="pubmed">7256544</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 1996 Jun 1;237(2):260-73</Citation><ArticleIdList><ArticleId IdType="pubmed">8660575</ArticleId></ArticleIdList></Reference><Reference><Citation>Semin Immunol. 2016 Jun;28(3):208-22</Citation><ArticleIdList><ArticleId IdType="pubmed">27321574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Microbiol. 2010 Jun;76(6):1387-97</Citation><ArticleIdList><ArticleId IdType="pubmed">20158613</ArticleId></ArticleIdList></Reference><Reference><Citation>Protein Eng. 1994 Aug;7(8):991-6</Citation><ArticleIdList><ArticleId IdType="pubmed">7528919</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Rev. 2009 Mar 11;109(3):839-60</Citation><ArticleIdList><ArticleId IdType="pubmed">19196002</ArticleId></ArticleIdList></Reference><Reference><Citation>Annu Rev Immunol. 1997;15:675-705</Citation><ArticleIdList><ArticleId IdType="pubmed">9143704</ArticleId></ArticleIdList></Reference><Reference><Citation>J Bacteriol. 2000 Jun;182(11):3254-8</Citation><ArticleIdList><ArticleId IdType="pubmed">10809707</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 1995 Apr 28;270(17):9862-7</Citation><ArticleIdList><ArticleId IdType="pubmed">7730368</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Invest. 1970 Dec;49(12):2427-36</Citation><ArticleIdList><ArticleId IdType="pubmed">4098172</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Immunol. 2019 Oct;114:341-352</Citation><ArticleIdList><ArticleId IdType="pubmed">31446305</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Biochem. 2009 Nov 15;394(2):287-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19627979</ArticleId></ArticleIdList></Reference><Reference><Citation>FASEB J. 2010 Aug;24(8):2839-48</Citation><ArticleIdList><ArticleId IdType="pubmed">20339024</ArticleId></ArticleIdList></Reference><Reference><Citation>PLoS Pathog. 2017 Aug 14;13(8):e1006493</Citation><ArticleIdList><ArticleId IdType="pubmed">28806402</ArticleId></ArticleIdList></Reference><Reference><Citation>Br J Pharmacol. 2007 Oct;152(4):429-48</Citation><ArticleIdList><ArticleId IdType="pubmed">17603557</ArticleId></ArticleIdList></Reference><Reference><Citation>Shock. 2007 Oct;28(4):418-25</Citation><ArticleIdList><ArticleId IdType="pubmed">17558345</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 2002 Oct;269(19):4839-51</Citation><ArticleIdList><ArticleId IdType="pubmed">12354115</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Mol Immunol. 2020 Nov;17(11):1180-1182</Citation><ArticleIdList><ArticleId IdType="pubmed">32963357</ArticleId></ArticleIdList></Reference><Reference><Citation>Transplantation. 2020 Oct 21;:</Citation><ArticleIdList><ArticleId IdType="pubmed">33093408</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1214-8</Citation><ArticleIdList><ArticleId IdType="pubmed">8108389</ArticleId></ArticleIdList></Reference><Reference><Citation>J Immunol. 1985 May;134(5):3325-31</Citation><ArticleIdList><ArticleId IdType="pubmed">3884709</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2011 May 31;50(21):4402-10</Citation><ArticleIdList><ArticleId IdType="pubmed">21506553</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 1995 Apr 14;38(8):1309-18</Citation><ArticleIdList><ArticleId IdType="pubmed">7537332</ArticleId></ArticleIdList></Reference><Reference><Citation>Anal Chem. 2003 Nov 1;75(21):5817-24</Citation><ArticleIdList><ArticleId IdType="pubmed">14588022</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1993 Apr;61(4):1421-6</Citation><ArticleIdList><ArticleId IdType="pubmed">8454345</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2020 Dec;588(7836):146-150</Citation><ArticleIdList><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>Trials. 2020 Jul 13;21(1):639</Citation><ArticleIdList><ArticleId IdType="pubmed">32660611</ArticleId></ArticleIdList></Reference><Reference><Citation>Infect Immun. 1992 Dec;60(12):5219-23</Citation><ArticleIdList><ArticleId IdType="pubmed">1452354</ArticleId></ArticleIdList></Reference><Reference><Citation>Methods Mol Biol. 1999;112:531-52</Citation><ArticleIdList><ArticleId IdType="pubmed">10027275</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2015 Sep 29;6:8322</Citation><ArticleIdList><ArticleId IdType="pubmed">26415554</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Biochem. 1994 Feb 1;219(3):897-904</Citation><ArticleIdList><ArticleId IdType="pubmed">8112341</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochemistry. 2008 Jun 24;47(25):6628-36</Citation><ArticleIdList><ArticleId IdType="pubmed">18507395</ArticleId></ArticleIdList></Reference><Reference><Citation>J Mol Biol. 2009 Feb 27;386(3):754-72</Citation><ArticleIdList><ArticleId IdType="pubmed">19152799</ArticleId></ArticleIdList></Reference><Reference><Citation>J Biol Chem. 2006 May 19;281(20):14215-23</Citation><ArticleIdList><ArticleId IdType="pubmed">16565520</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">35336009</PMID><DateRevised><Year>2022</Year><Month>03</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>13</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>Formation of Ciprofloxacin-Isonicotinic Acid Cocrystal Using Mechanochemical Synthesis Routes-An Investigation into Critical Process Parameters.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">634</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics14030634</ELocationID><Abstract><AbstractText>The mechanochemical synthesis of cocrystals has been introduced as a promising approach of formulating poorly water-soluble active pharmaceutical ingredients (APIs). In this study, hot-melt extrusion (HME) as a continuous process and grinding and ball milling as batch processes were employed to explore the feasibility of cocrystallization. Ciprofloxacin (CIP) and isonicotinic acid (INCA) were selected as the model API and coformer. CIP-INCA cocrystal was produced in all techniques. It was revealed that higher cocrystal content could be achieved at longer durations of grinding and ball milling. However, milling for more than 10 min led to increased co-amorphous content instead of cocrystal. A design of experiment (DoE) approach was used for deciphering the complex correlation of screw configuration, screw speed, and temperature as HME process parameters and their respective effect on final relative cocrystal yield. Statistical analysis showed that screw configuration, temperature, and their interaction were the most critical factors affecting cocrystallization. Interestingly, screw speed had minimal impact on the relative cocrystallization yield. Cocrystallization led to increased dissolution rate of CIP in phosphate buffer up to 2.5-fold. Overall, this study shed a light on the potential of mechanochemical synthesis techniques with special focus on HME as a continuous process for producing cocrystals.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karimi-Jafari</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Synthesis &amp; Solid State Pharmaceutical Centre (SSPC), Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ziaee</LastName><ForeName>Ahmad</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-6385-6370</Identifier><AffiliationInfo><Affiliation>Synthesis &amp; Solid State Pharmaceutical Centre (SSPC), Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Emmet</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Synthesis &amp; Solid State Pharmaceutical Centre (SSPC), Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Croker</LastName><ForeName>Denise</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Synthesis &amp; Solid State Pharmaceutical Centre (SSPC), Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Gavin</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Synthesis &amp; Solid State Pharmaceutical Centre (SSPC), Department of Chemical Sciences, Bernal Institute, University of Limerick, V94 T9PX Limerick, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SFI SSPC2 12/RC/2275</GrantID><Acronym>SFI_</Acronym><Agency>Science Foundation Ireland</Agency><Country>Ireland</Country></Grant><Grant><GrantID>15/US-C2C/I3133</GrantID><Agency>National Science Foundation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ball milling</Keyword><Keyword MajorTopicYN="N">cocrystal</Keyword><Keyword MajorTopicYN="N">continuous manufacturing</Keyword><Keyword MajorTopicYN="N">design of experiment</Keyword><Keyword MajorTopicYN="N">green chemistry</Keyword><Keyword MajorTopicYN="N">grinding</Keyword><Keyword MajorTopicYN="N">hot-melt extrusion</Keyword><Keyword MajorTopicYN="N">mechanochemical synthesis</Keyword><Keyword MajorTopicYN="N">solid state chemistry</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>01</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>03</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>03</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>26</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>27</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35336009</ArticleId><ArticleId IdType="pii">pharmaceutics14030634</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics14030634</ArticleId><ArticleId IdType="pmc">PMC8949855</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Am Chem Soc. 2003 Jul 16;125(28):8456-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12848550</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2014 Apr;86(3):532-43</Citation><ArticleIdList><ArticleId IdType="pubmed">24380678</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2019 Jul 20;566:745-755</Citation><ArticleIdList><ArticleId IdType="pubmed">31212053</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Med Chem. 2018 Feb 25;146:599-612</Citation><ArticleIdList><ArticleId IdType="pubmed">29407984</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2013 Mar 28;56(6):2690-4</Citation><ArticleIdList><ArticleId IdType="pubmed">23432334</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2012 Nov 15;438(1-2):307-26</Citation><ArticleIdList><ArticleId IdType="pubmed">22982489</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutics. 2011 Aug 31;3(3):582-600</Citation><ArticleIdList><ArticleId IdType="pubmed">24310598</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Rev Drug Discov. 2015 Jul;14(7):475-86</Citation><ArticleIdList><ArticleId IdType="pubmed">26091267</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2021 Aug;11(8):2537-2564</Citation><ArticleIdList><ArticleId IdType="pubmed">34522597</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Sci. 2016 Dec 1;95:28-35</Citation><ArticleIdList><ArticleId IdType="pubmed">27531419</ArticleId></ArticleIdList></Reference><Reference><Citation>Sci Total Environ. 2017 Dec 15;605-606:368-375</Citation><ArticleIdList><ArticleId IdType="pubmed">28668748</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2010 Apr;99(4):1942-54</Citation><ArticleIdList><ArticleId IdType="pubmed">19894277</ArticleId></ArticleIdList></Reference><Reference><Citation>J Fluoresc. 2011 Nov;21(6):2117-22</Citation><ArticleIdList><ArticleId IdType="pubmed">21750893</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutics. 2014 Jul 14;6(3):416-35</Citation><ArticleIdList><ArticleId IdType="pubmed">25025400</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Biopharm. 2007 Aug;67(1):112-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17292592</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2007 May-Jun;4(3):317-22</Citation><ArticleIdList><ArticleId IdType="pubmed">17497799</ArticleId></ArticleIdList></Reference><Reference><Citation>Adv Drug Deliv Rev. 2001 May 16;48(1):27-42</Citation><ArticleIdList><ArticleId IdType="pubmed">11325475</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 1997 Jan;86(1):1-12</Citation><ArticleIdList><ArticleId IdType="pubmed">9002452</ArticleId></ArticleIdList></Reference><Reference><Citation>Eur J Pharm Sci. 2015 Sep 18;77:112-21</Citation><ArticleIdList><ArticleId IdType="pubmed">26066411</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutics. 2021 Apr 15;13(4):</Citation><ArticleIdList><ArticleId IdType="pubmed">33921031</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Biomed Anal. 2003 Sep 15;33(1):125-30</Citation><ArticleIdList><ArticleId IdType="pubmed">12946539</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2013 Oct 7;10(10):3640-54</Citation><ArticleIdList><ArticleId IdType="pubmed">23947816</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2014 Dec 30;477(1-2):1-11</Citation><ArticleIdList><ArticleId IdType="pubmed">25304093</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2011 Aug;100(8):3160-3176</Citation><ArticleIdList><ArticleId IdType="pubmed">21394722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">30020788</PMID><DateCompleted><Year>2019</Year><Month>08</Month><Day>02</Day></DateCompleted><DateRevised><Year>2019</Year><Month>08</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-8392</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>9</Issue><PubDate><Year>2018</Year><Month>09</Month><Day>04</Day></PubDate></JournalIssue><Title>Molecular pharmaceutics</Title><ISOAbbreviation>Mol Pharm</ISOAbbreviation></Journal><ArticleTitle>Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.</ArticleTitle><Pagination><MedlinePgn>3796-3812</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.8b00306</ELocationID><Abstract><AbstractText>The formulation of oral amorphous solid dispersions (ASD) includes the use of excipients to improve physical stability and enhance bioavailability. Combinations of excipients (polymers and surfactants) are often employed in pharmaceutical products to improve the delivery of poorly water-soluble drugs. However, additive interactions in multicomponent ASD systems have not been extensively studied and may promote crystallization in an unpredictable manner, which in turn may affect the physical stability and dissolution profile of the product. The main aim of this study was to understand the effect of different surfactant and polymer combinations on the solid-state properties and dissolution behavior of ternary spray-dried solid dispersions of dipyridamole and cinnarizine. The surfactants chosen for this study were sodium dodecyl sulfate and poloxamer 188, and the model polymers used were polyvinylpyrrolidone K30 and hydroxypropyl methylcellulose K100. The spray-dried ternary dispersions maintained higher supersaturation compared to either the crystalline drug equilibrium solubility or their respective physical mixtures. However, rapid and variable dissolution behavior was observed for different formulations. The maximum supersaturation level was observed with drug-polymer-polymer ternary dispersions. On the other hand, incorporating the surfactant into binary (drug-polymer) and ternary (drug-polymer-polymer) ASDs adversely affected the physical stability and dissolution by promoting crystallization. On the basis of these observations, a thorough investigation into the impact of combinations of additives on amorphous drug crystallization during dissolution and stability studies is recommended in order to develop optimized formulations of supersaturating dosage forms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baghel</LastName><ForeName>Shrawan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6713-7472</Identifier><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) , Waterford Institute of Technology , Cork Road , Waterford , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cathcart</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) , Waterford Institute of Technology , Cork Road , Waterford , Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Reilly</LastName><ForeName>Niall J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Pharmaceutical and Molecular Biotechnology Research Centre (PMBRC) , Waterford Institute of Technology , Cork Road , Waterford , Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>07</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharm</MedlineTA><NlmUniqueID>101197791</NlmUniqueID><ISSNLinking>1543-8384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011108">Polymers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013501">Surface-Active Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>368GB5141J</RegistryNumber><NameOfSubstance UI="D012967">Sodium Dodecyl Sulfate</NameOfSubstance></Chemical><Chemical><RegistryNumber>3NXW29V3WO</RegistryNumber><NameOfSubstance UI="D065347">Hypromellose Derivatives</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D002626" MajorTopicYN="N">Chemistry, Pharmaceutical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003460" MajorTopicYN="N">Crystallization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065347" MajorTopicYN="N">Hypromellose Derivatives</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011108" MajorTopicYN="N">Polymers</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012967" MajorTopicYN="N">Sodium Dodecyl Sulfate</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013501" MajorTopicYN="N">Surface-Active Agents</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">amorphous solid dispersion</Keyword><Keyword MajorTopicYN="Y">crystallization</Keyword><Keyword MajorTopicYN="Y">dissolution</Keyword><Keyword MajorTopicYN="Y">drug−polymer interaction</Keyword><Keyword MajorTopicYN="Y">nuclear magnetic resonance</Keyword><Keyword MajorTopicYN="Y">spray drying</Keyword><Keyword MajorTopicYN="Y">supersaturation</Keyword><Keyword MajorTopicYN="Y">surfactant</Keyword><Keyword MajorTopicYN="Y">synergism</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>8</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30020788</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00306</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" IndexingMethod="Automated" Owner="NLM"><PMID Version="1">34571316</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1095-7103</ISSN><JournalIssue CitedMedium="Internet"><Volume>607</Volume><Issue>Pt 2</Issue><PubDate><Year>2022</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of colloid and interface science</Title><ISOAbbreviation>J Colloid Interface Sci</ISOAbbreviation></Journal><ArticleTitle>Balanced lipase interactions for degradation-controlled paclitaxel release from lipid cubic phase formulations.</ArticleTitle><Pagination><MedlinePgn>978-991</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">S0021-9797(21)01481-8</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcis.2021.09.024</ELocationID><Abstract><AbstractText>Lipid cubic phase (LCP) formulations enhance the intestinal solubility and bioavailability of hydrophobic drugs by reducing precipitation and facilitating their mass transport to the intestinal surface for absorption. LCPs with an ester linkage connecting the acyl chain to the glycerol backbone (monoacylglycerols), are susceptible to chemical digestion by several lipolytic enzymes including lipases, accelerating the release of hydrophobic agents from the lipid bilayers of the matrix. Unlike regular enzymes that transform soluble substrates, lipolytic enzymes act at the interface of water and insoluble lipid. Therefore, compounds that bind to this interface can enhance or inhibit the activity of enzymes to varying extent. Here, we explore how the lipolysis rate can be tuned by the interfacial interaction of porcine pancreatic lipase with monoolein LCPs containing a known lipase inhibitor, tetrahydrolipstatin. Release of the Biopharmaceutical Classification System (BCS) class IV drug, paclitaxel, from the inhibitor-modified LCP was examined in the presence of lipase and its effectors colipase and calcium. By combining experimental dynamic digestion studies, thermodynamic measurements and molecular dynamics simulations of the competitive inhibition of lipase by tetrahydrolipstatin, we reveal the role and mode of action of lipase effectors in creating a precisely-balanced degradation-controlled LCP release system for the poorly soluble paclitaxel drug.</AbstractText><CopyrightInformation>Copyright © 2021 Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dully</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemical Sciences, SSPC the Science Foundation Ireland Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhattacharya</LastName><ForeName>Shayon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Physics, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verma</LastName><ForeName>Vivek</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Chemical Sciences, SSPC the Science Foundation Ireland Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Murray</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>COOK Ireland Limited, O'Halloran Rd, Castletroy, Co., Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thompson</LastName><ForeName>Damien</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physics, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland. Electronic address: damien.thompson@ul.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soulimane</LastName><ForeName>Tewfik</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Chemical Sciences, SSPC the Science Foundation Ireland Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland. Electronic address: tewfik.soulimane@ul.ie.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Sarah P</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Department of Chemical Sciences, SSPC the Science Foundation Ireland Research Centre for Pharmaceuticals, Bernal Institute, University of Limerick, Limerick V94 T9PX, Ireland. Electronic address: sarah.hudson@ul.ie.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Colloid Interface Sci</MedlineTA><NlmUniqueID>0043125</NlmUniqueID><ISSNLinking>0021-9797</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.1.1.3</RegistryNumber><NameOfSubstance UI="D008049">Lipase</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008049" MajorTopicYN="Y">Lipase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="N">Lipids</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008066" MajorTopicYN="N">Lipolysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010179" MajorTopicYN="N">Pancreas</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013552" MajorTopicYN="N">Swine</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Binding energy</Keyword><Keyword MajorTopicYN="N">Colipase</Keyword><Keyword MajorTopicYN="N">Controlled release</Keyword><Keyword MajorTopicYN="N">Density functional theory</Keyword><Keyword MajorTopicYN="N">Lipid cubic phase</Keyword><Keyword MajorTopicYN="N">Molecular dynamics</Keyword><Keyword MajorTopicYN="N">Paclitaxel</Keyword><Keyword MajorTopicYN="N">Pancreatic lipase</Keyword><Keyword MajorTopicYN="N">Predictive modelling</Keyword><Keyword MajorTopicYN="N">Tetrahydrolipstatin</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>06</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>09</Month><Day>03</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>09</Month><Day>04</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>9</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>9</Month><Day>27</Day><Hour>20</Hour><Minute>17</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34571316</ArticleId><ArticleId IdType="pii">S0021-9797(21)01481-8</ArticleId><ArticleId IdType="doi">10.1016/j.jcis.2021.09.024</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34267600</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1528-7483</ISSN><JournalIssue CitedMedium="Print"><Volume>21</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Crystal growth &amp; design</Title><ISOAbbreviation>Cryst Growth Des</ISOAbbreviation></Journal><ArticleTitle>Factors Controlling Persistent Needle Crystal Growth: The Importance of Dominant One-Dimensional Secondary Bonding, Stacked Structures, and van der Waals Contact.</ArticleTitle><Pagination><MedlinePgn>3449-3460</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.cgd.1c00217</ELocationID><Abstract><AbstractText>Needle crystals can cause filtering and handling problems in industrial settings, and the factors leading to a needle crystal morphology have been investigated. The crystal growth of the amide and methyl, ethyl, isopropyl, and t-butyl esters of diflunisal have been examined, and needle growth has been observed for all except the t-butyl ester. Their crystal structures show that the t-butyl ester is the only structure that does not contain molecular stacking. A second polymorph of a persistent needle forming phenylsulfonamide with a block like habit has been isolated. The structure analysis has been extended to known needle forming systems from the literature. The intermolecular interactions in needle forming structures have been analyzed using the PIXEL program, and the properties driving needle crystal growth were found to include a 1D motif with interaction energy greater than -30 kJ/mol, at least 50% vdW contact between the motif neighbors, and a filled unit cell which is a monolayer. Crystal structures are classified into persistent and controllable needle formers. Needle growth in the latter class can be controlled by choice of solvent. The factors shown here to be drivers of needle growth will help in the design of processes for the production of less problematic crystal products.</AbstractText><CopyrightInformation>© 2021 The Authors. Published by American Chemical Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Civati</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>School of Chemistry, National University of Ireland, Galway H91TK33, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Limerick V94T9PX, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Malley</LastName><ForeName>Ciaran</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>School of Chemistry, National University of Ireland, Galway H91TK33, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erxleben</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-7309-8972</Identifier><AffiliationInfo><Affiliation>School of Chemistry, National University of Ireland, Galway H91TK33, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Limerick V94T9PX, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McArdle</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">https://orcid.org/0000-0002-3565-0527</Identifier><AffiliationInfo><Affiliation>School of Chemistry, National University of Ireland, Galway H91TK33, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cryst Growth Des</MedlineTA><NlmUniqueID>101261892</NlmUniqueID><ISSNLinking>1528-7483</ISSNLinking></MedlineJournalInfo><CoiStatement>The authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>02</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>16</Day><Hour>6</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34267600</ArticleId><ArticleId IdType="doi">10.1021/acs.cgd.1c00217</ArticleId><ArticleId IdType="pmc">PMC8273860</ArticleId></ArticleIdList><?pmcsd ?><ReferenceList><Reference><Citation>J Am Chem Soc. 2005 Feb 16;127(6):1975-82</Citation><ArticleIdList><ArticleId IdType="pubmed">15701033</ArticleId></ArticleIdList></Reference><Reference><Citation>Cryst Growth Des. 2016 Jun 1;16(6):3480-3496</Citation><ArticleIdList><ArticleId IdType="pubmed">28663717</ArticleId></ArticleIdList></Reference><Reference><Citation>ChemCatChem. 2013 Aug;5(8):2405-2409</Citation><ArticleIdList><ArticleId IdType="pubmed">24159364</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr B Struct Sci Cryst Eng Mater. 2020 Feb 1;76(Pt 1):65-75</Citation><ArticleIdList><ArticleId IdType="pubmed">32831242</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 1982 Jul 30;217(4558):401-7</Citation><ArticleIdList><ArticleId IdType="pubmed">17782965</ArticleId></ArticleIdList></Reference><Reference><Citation>J Chem Theory Comput. 2015 Aug 11;11(8):3696-713</Citation><ArticleIdList><ArticleId IdType="pubmed">26574453</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2014 Sep 2;11(9):3009-16</Citation><ArticleIdList><ArticleId IdType="pubmed">25090160</ArticleId></ArticleIdList></Reference><Reference><Citation>Chem Asian J. 2015 Oct;10(10):2176-81</Citation><ArticleIdList><ArticleId IdType="pubmed">25919633</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr C Struct Chem. 2014 Mar;70(Pt 3):323-5</Citation><ArticleIdList><ArticleId IdType="pubmed">24594727</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr B. 1968 Mar 15;24(3):442-9</Citation><ArticleIdList><ArticleId IdType="pubmed">5756978</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr B. 2001 Jun;57(Pt 3):410-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11373402</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr B. 2001 Jun;57(Pt 3):346-52</Citation><ArticleIdList><ArticleId IdType="pubmed">11373393</ArticleId></ArticleIdList></Reference><Reference><Citation>Faraday Discuss. 2015;179:79-114</Citation><ArticleIdList><ArticleId IdType="pubmed">25920721</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2017 Aug 7;528(1-2):312-321</Citation><ArticleIdList><ArticleId IdType="pubmed">28603011</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Crystallogr C. 1988 Dec 15;44 ( Pt 12):2138-40</Citation><ArticleIdList><ArticleId IdType="pubmed">2481477</ArticleId></ArticleIdList></Reference><Reference><Citation>Angew Chem Int Ed Engl. 2018 Aug 6;57(32):10112-10117</Citation><ArticleIdList><ArticleId IdType="pubmed">29756395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nature. 2005 Nov 3;438(7064):70-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16267550</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatics. 2014 Oct 15;30(20):2981-2</Citation><ArticleIdList><ArticleId IdType="pubmed">24996895</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2019 May;108(5):1779-1787</Citation><ArticleIdList><ArticleId IdType="pubmed">30590015</ArticleId></ArticleIdList></Reference><Reference><Citation>Angew Chem Int Ed Engl. 2006 Mar 13;45(12):1844-54</Citation><ArticleIdList><ArticleId IdType="pubmed">16470749</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32672449</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2021</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-510X</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>15</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Inorganic chemistry</Title><ISOAbbreviation>Inorg Chem</ISOAbbreviation></Journal><ArticleTitle>Synthesis, Characterization, and Biological Profiling of Ruthenium(II)-Based 4-Nitro- and 4-Amino-1,8-naphthalimide Conjugates.</ArticleTitle><Pagination><MedlinePgn>10874-10893</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.inorgchem.0c01395</ELocationID><Abstract><AbstractText>We report the synthesis, photophysical characterization, and biological evaluation of four DNA-binding ruthenium(II) polypyridyl 4-nitro- and 4-amino-1,8-naphthalimide conjugates. A meta arrangement around the ring connecting the 1,8-naphthalimide to a bipyridine ligand creates a cleft, the result of which renders the shape of the complex complementary to that of DNA. We have demonstrated that each complex exhibits water solubility and a distinctive set of photophysical properties that has allowed the nature of their interaction with DNA to be probed by various ground- and excited-state titrations. Furthermore, by varying the ancillary ligands, we also demonstrate their ability to act as DNA photocleavers, where all compounds have been found to cleave supercoiled DNA with high efficiency. Detailed cellular uptake experiments revealed that the conjugates accumulate in the cytoplasm and nucleus of HeLa cells, showing characteristic red metal-to-ligand charge-transfer emission, and also exhibit photoactivated cytotoxicity within the cells upon irradiation at 450 nm. A comparison between the meta and para arrangements of the 1,8-naphthalimide moiety relative to the Ru(II) center suggests increased DNA binding in the case of the meta arrangement; however, bipyridine-4-amino-1,8-naphthalimide conjugates appear to show superior phototoxicity in comparison to their 4-nitro derivatives.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elmes</LastName><ForeName>Robert B P</ForeName><Initials>RBP</Initials><Identifier Source="ORCID">http://orcid.org/0000-0001-7898-903X</Identifier><AffiliationInfo><Affiliation>Department of Chemistry, Maynooth University, National University of Ireland, Maynooth W23 F2K8, County Kildare, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Limerick, County Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Gary J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin (TCD), The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erby</LastName><ForeName>Maria Luisa</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frimannsson</LastName><ForeName>Daniel O</ForeName><Initials>DO</Initials><AffiliationInfo><Affiliation>School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin (TCD), The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Institute of Molecular Medicine, St. James's Hospital, Trinity College Dublin, Dublin 8, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kitchen</LastName><ForeName>Jonathan A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7139-5666</Identifier><AffiliationInfo><Affiliation>School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin (TCD), The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Chemistry, School of Natural and Computational Sciences, Massey University, Auckland 0745, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawler</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Health Sciences, Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University of Belfast, Belfast BT9 7BL, Northern Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>D Clive</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinn</LastName><ForeName>Susan J</ForeName><Initials>SJ</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-7773-8842</Identifier><AffiliationInfo><Affiliation>School of Chemistry, University College Dublin, Dublin 4, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Limerick, County Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gunnlaugsson</LastName><ForeName>Thorfinnur</ForeName><Initials>T</Initials><Identifier Source="ORCID">http://orcid.org/0000-0003-4814-6853</Identifier><AffiliationInfo><Affiliation>School of Chemistry, Trinity Biomedical Sciences Institute, Trinity College Dublin (TCD), The University of Dublin, Dublin 2, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Limerick, County Limerick, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Inorg Chem</MedlineTA><NlmUniqueID>0366543</NlmUniqueID><ISSNLinking>0020-1669</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D056831">Coordination Complexes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053644">Naphthalimides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009574">Nitro Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015363">Quinolones</NameOfSubstance></Chemical><Chemical><RegistryNumber>1742-95-6</RegistryNumber><NameOfSubstance UI="C086538">4-amino-1,8-naphthalimide</NameOfSubstance></Chemical><Chemical><RegistryNumber>7UI0TKC3U5</RegistryNumber><NameOfSubstance UI="D012428">Ruthenium</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>9753I242R5</RegistryNumber><NameOfSubstance UI="D015057">1-Naphthylamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015057" MajorTopicYN="N">1-Naphthylamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056831" MajorTopicYN="N">Coordination Complexes</DescriptorName><QualifierName UI="Q000138" MajorTopicYN="N">chemical synthesis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006367" MajorTopicYN="N">HeLa Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020014" MajorTopicYN="N">K562 Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053644" MajorTopicYN="N">Naphthalimides</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009574" MajorTopicYN="N">Nitro Compounds</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061848" MajorTopicYN="N">Optical Imaging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012428" MajorTopicYN="N">Ruthenium</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="Y">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32672449</ArticleId><ArticleId IdType="doi">10.1021/acs.inorgchem.0c01395</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32633973</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1543-8392</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>08</Month><Day>03</Day></PubDate></JournalIssue><Title>Molecular pharmaceutics</Title><ISOAbbreviation>Mol Pharm</ISOAbbreviation></Journal><ArticleTitle>Comparison of Drug Release and Adsorption under Supersaturating Conditions for Ordered Mesoporous Silica with Indomethacin or Indomethacin Methyl Ester.</ArticleTitle><Pagination><MedlinePgn>3062-3074</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.molpharmaceut.0c00489</ELocationID><Abstract><AbstractText>Incomplete drug release from mesoporous silica systems has been observed in several studies. This work aims to increase the understanding of this phenomenon by investigating the mechanism of drug-silica interactions and adsorption behavior from supersaturated aqueous solutions of two similar drug molecules with different hydrogen bonding capabilities. Drug-silica interactions between indomethacin or its methyl ester and SBA-15 were investigated using spectroscopic techniques (infrared, fluorescence and X-ray photoelectron) and adsorption experiments. The results demonstrate that the predominant mechanism of interaction of both drugs with silica is hydrogen bonding between drug acceptor carbonyl groups with donor groups on the silica surface. The presence of a drug hydrogen bond donor group did not enhance drug adsorption. No evidence was obtained for drug adsorption through nonspecific hydrophobic interactions. Drug adsorption onto the silica surface was investigated under supersaturating conditions through the generation of adsorption isotherms. Similar adsorption isotherms were observed for each compound when the concentration scale was normalized to the drug amorphous solubility. In other words, the equilibrium between the drug adsorbed on the silica surface and free drug in solution was related to the drug activity in solution. The high tendency of the drug to adsorb when the solution is supersaturated was, in turn, found to limit the extent of drug release during dissolution under nonsink conditions. Thus, adsorption provides an explanation for incomplete drug release.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Carol A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-7404-3885</Identifier><AffiliationInfo><Affiliation>SSPC Pharm. Res. Centre, School of Pharmacy, University College Cork, Cork T12 YN60, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zemlyanov</LastName><ForeName>Dmitry Y</ForeName><Initials>DY</Initials><Identifier Source="ORCID">0000-0002-1221-9195</Identifier><AffiliationInfo><Affiliation>Birck Nanotechnology Center, Purdue University, West Lafayette 47907, Indiana, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crean</LastName><ForeName>Abina M</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-6171-0303</Identifier><AffiliationInfo><Affiliation>SSPC Pharm. Res. Centre, School of Pharmacy, University College Cork, Cork T12 YN60, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Lynne S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-4568-6021</Identifier><AffiliationInfo><Affiliation>Department of Industrial and Physical Pharmacy, College of Pharmacy, Purdue University, West Lafayette 47907, Indiana, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mol Pharm</MedlineTA><NlmUniqueID>101197791</NlmUniqueID><ISSNLinking>1543-8384</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004952">Esters</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C509969">SBA-15</NameOfSubstance></Chemical><Chemical><RegistryNumber>059QF0KO0R</RegistryNumber><NameOfSubstance UI="D014867">Water</NameOfSubstance></Chemical><Chemical><RegistryNumber>7631-86-9</RegistryNumber><NameOfSubstance UI="D012822">Silicon Dioxide</NameOfSubstance></Chemical><Chemical><RegistryNumber>XXE1CET956</RegistryNumber><NameOfSubstance UI="D007213">Indomethacin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000327" MajorTopicYN="N">Adsorption</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065546" MajorTopicYN="N">Drug Liberation</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004952" MajorTopicYN="N">Esters</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057927" MajorTopicYN="N">Hydrophobic and Hydrophilic Interactions</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007213" MajorTopicYN="N">Indomethacin</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016062" MajorTopicYN="N">Porosity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012822" MajorTopicYN="N">Silicon Dioxide</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012995" MajorTopicYN="N">Solubility</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014867" MajorTopicYN="N">Water</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">adsorption</Keyword><Keyword MajorTopicYN="Y">mesoporous silica</Keyword><Keyword MajorTopicYN="Y">release</Keyword><Keyword MajorTopicYN="Y">supersaturation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32633973</ArticleId><ArticleId IdType="doi">10.1021/acs.molpharmaceut.0c00489</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32121578</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1999-4923</ISSN><JournalIssue CitedMedium="Print"><Volume>12</Volume><Issue>3</Issue><PubDate><Year>2020</Year><Month>Mar</Month><Day>01</Day></PubDate></JournalIssue><Title>Pharmaceutics</Title><ISOAbbreviation>Pharmaceutics</ISOAbbreviation></Journal><ArticleTitle>The Effect of Cooling on the Degree of Crystallinity, Solid-State Properties, and Dissolution Rate of Multi-Component Hot-Melt Extruded Solid Dispersions.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">E212</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pharmaceutics12030212</ELocationID><Abstract><AbstractText><b>:</b> The effect of cooling on the degree of crystallinity, solid-state and dissolution properties of multi-component hot-melt extruded solid dispersions [SD] is of great interest for the successful formulation of amorphous SDs and is an area that is unreported, especially in the context of improving the stability of these specific systems. The thermal solid-state properties, degree of crystallinity, drug-polymer interactions, solubility and physical stability over time were investigated. X-ray powder diffraction [XRPD] and hyper differential scanning calorimetry [DSC] confirmed that indomethacin [INM] was converted to the amorphous state; however, the addition of poloxamer 407 [P407] had a significant effect on the degree of crystallinity and the solubility of the SD formulations. Spectroscopy studies identified the mechanism of interaction and solubility studies, showing a higher dissolution rate compared to amorphous and pure INM in pH 1.2 with a kinetic solubility of 20.63 µg/mL and 34.7 µg/mL after 3 and 24 h. XRPD confirmed that INM remained amorphous after 5 months stability testing in solid solutions with Poly(vinylpyrrolidone-co-vinyl acetate) [PVP VA64] and Plasdone S-630 [PL-S630]. Although cooling had a significant effect on the degree of crystallinity and on solubility of INM, the cooling method used did not have any significant effect on the amorphous stability of INM over time.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>Dean</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Materials Research Institute, Athlone Institute of Technology, Athlone, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Mark</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Walker</LastName><ForeName>Gavin M</ForeName><Initials>GM</Initials><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyons</LastName><ForeName>John G</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Materials Research Institute, Athlone Institute of Technology, Athlone, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Higginbotham</LastName><ForeName>Clement L</ForeName><Initials>CL</Initials><AffiliationInfo><Affiliation>Materials Research Institute, Athlone Institute of Technology, Athlone, Ireland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synthesis and Solid State Pharmaceutical Centre (SSPC), Bernal Institute, University of Limerick, Limerick, Ireland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>12/RC/2275</GrantID><Acronym>SFI_</Acronym><Agency>Science Foundation Ireland</Agency><Country>Ireland</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceutics</MedlineTA><NlmUniqueID>101534003</NlmUniqueID><ISSNLinking>1999-4923</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amorphous</Keyword><Keyword MajorTopicYN="N">cooling</Keyword><Keyword MajorTopicYN="N">crystallization</Keyword><Keyword MajorTopicYN="N">extrusion</Keyword><Keyword MajorTopicYN="N">glass transition</Keyword><Keyword MajorTopicYN="N">solid dispersion</Keyword><Keyword MajorTopicYN="N">solubility</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>02</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>3</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32121578</ArticleId><ArticleId IdType="pii">pharmaceutics12030212</ArticleId><ArticleId IdType="doi">10.3390/pharmaceutics12030212</ArticleId><ArticleId IdType="pmc">PMC7150909</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mol Pharm. 2015 Dec 7;12(12):4518-28</Citation><ArticleIdList><ArticleId IdType="pubmed">26512737</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Ind Pharm. 2015;41(9):1401-15</Citation><ArticleIdList><ArticleId IdType="pubmed">25853292</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS PharmSciTech. 2017 Nov;18(8):3258-3273</Citation><ArticleIdList><ArticleId IdType="pubmed">28584898</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2008 Jun;97(6):2286-98</Citation><ArticleIdList><ArticleId IdType="pubmed">17879977</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pharm Res. 2008 Nov;31(11):1497-507</Citation><ArticleIdList><ArticleId IdType="pubmed">19023548</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2010 Jan 4;383(1-2):161-9</Citation><ArticleIdList><ArticleId IdType="pubmed">19748557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2015 Feb 2;12(2):576-89</Citation><ArticleIdList><ArticleId IdType="pubmed">25535667</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 1999 Nov;88(11):1182-90</Citation><ArticleIdList><ArticleId IdType="pubmed">10564068</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Pharm. 2007 Oct 1;343(1-2):228-37</Citation><ArticleIdList><ArticleId IdType="pubmed">17597315</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2015 Feb 2;12(2):533-41</Citation><ArticleIdList><ArticleId IdType="pubmed">25569461</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm. 2009 Dec;59(4):453-61</Citation><ArticleIdList><ArticleId IdType="pubmed">19919934</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS PharmSciTech. 2014 Feb;15(1):52-64</Citation><ArticleIdList><ArticleId IdType="pubmed">24092522</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Pharm Sin B. 2014 Feb;4(1):18-25</Citation><ArticleIdList><ArticleId IdType="pubmed">26579360</ArticleId></ArticleIdList></Reference><Reference><Citation>Drug Dev Ind Pharm. 2013 Feb;39(2):218-27</Citation><ArticleIdList><ArticleId IdType="pubmed">22452601</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS PharmSciTech. 2016 Feb;17(1):133-47</Citation><ArticleIdList><ArticleId IdType="pubmed">26729533</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2016 Sep;105(9):2527-2544</Citation><ArticleIdList><ArticleId IdType="pubmed">26886314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2015 May 4;12(5):1377-90</Citation><ArticleIdList><ArticleId IdType="pubmed">25730138</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Sci. 2018 May;107(5):1372-1382</Citation><ArticleIdList><ArticleId IdType="pubmed">29410037</ArticleId></ArticleIdList></Reference><Reference><Citation>AAPS PharmSciTech. 2013 Jun;14(2):748-56</Citation><ArticleIdList><ArticleId IdType="pubmed">23615772</ArticleId></ArticleIdList></Reference><Reference><Citation>Mol Pharm. 2016 Mar 7;13(3):1166-75</Citation><ArticleIdList><ArticleId IdType="pubmed">26845251</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 2006 Dec;23(12):2709-28</Citation><ArticleIdList><ArticleId IdType="pubmed">17096184</ArticleId></ArticleIdList></Reference><Reference><Citation>J Control Release. 2015 Aug 10;211:85-93</Citation><ArticleIdList><ArticleId IdType="pubmed">26054795</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharm Res. 1997 Dec;14(12):1691-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9453055</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>